Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?

Journal of Alzheimer's Disease

Volumn 52, Issue 2, 2016, Pages 417-420

  Piazza, Fabrizio ^a,b   Winblad, Bengt ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ICAB Italy Study Group   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Aducanumab; adverse effects; Alzheimer's disease; amyloid related imaging abnormalities; anti A autoantibodies; cerebral amyloid angiopathy related inflammation; clinical trial; drug safety biomarkers; gantenerumab; immunotherapy

Indexed keywords

ADUCANUMAB; AMYLOID BETA PROTEIN; ANTIBODY; BIOLOGICAL MARKER; GANTENERUMAB; TAU PROTEIN; AMYLOID PROTEIN; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; HUMAN; IMMUNOTHERAPY; MONITORING; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RISK; SAFETY; SIDE EFFECT; BRAIN; DIAGNOSTIC IMAGING; IMMUNOLOGY; METABOLISM; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALZHEIMER DISEASE; AMYLOIDOGENIC PROTEINS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; BRAIN; HUMANS; IMMUNOTHERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84971280604     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160122     Document Type: Article

References (17)

1. Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, Tampieri D, Melançon D, Miaux Y, Rippon G, Black R, Lu Y, Brashear HR, Arrighi HM, Morris KA, Grundman M(2013) MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol 34, 1958-1965.
2. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, ThiesW, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7, 367-385.
3. DiFrancesco JC, Longoni M, Piazza F (2015) Anti-Abeta autoantibodies in amyloid related imaging abnormalities (ARIA): Candidate biomarker for immunotherapy in Alzheimer's disease and cerebral amyloid angiopathy. Frontiers Neurol 6, 207.
4. Lasser R, Ostrowitzki S, Scheltens P, Boada M, Dubois B, Dorflinger E, Balas B, Nikolcheva T, Volz D, Ashford E, Retout S, Edgar C, Garibaldi G, Fontoura P, Santarelli L (2015) OC4: Efficacy and safety of gantenerumab from the phase 3 SCarlet RoAD trial, a study of gantenerumab in patients with prodromal AD. J Prev Alzheimers Dis 2, 275-276.
5. Nikolcheva T, Lasser R, Ostrowitzki S, Scheltens P, Boada M, Dubois B, Dorflinger E, Volz D, Eichenlaub U, Rabe C, Bittner T, Schmitz M, Edgar C, Garibaldi G, Fontoura P, Santarelli L (2015) OC5: CSF and amyloid PET biomarker data from the phase 3 SCarlet RoAD trial, a study of gantenerumab in patients with prodromal AD. J Prev Alzheimers Dis 2, 276.
6. Viglietta V, Miao X, Chen T, O'gorman J,Williams L, Ling L, Sevigny J (2015) OC8: Randomized, placebo-controlled, phase 1b study of the anti-beta-amyloid antibody aducanumab (BIIB037) in patients with prodromal or mild Alzheimer's disease: Interim results from a subpopulation of patients with early Alzheimer's disease meeting phase 3 study entry criteria. J Prev Alzheimers Dis 2, 277-278.
7. Sevigny J, Chiao P, Williams L, Chen T, Ling Y, O'gorman J, Hock C, Nitsch RM, Sandrock A (2015) OC19: Randomized, placebo-controlled, phase 1b study of the anti-beta-amyloid antibody aducanumab (BIIB037) in patients with prodromal or mild Alzheimer's disease: Interim results. J Prev Alzheimers Dis 2, 283
8. Viglietta V, O'gorman J, Williams L, Doody R, Salloway S, Barkhof F, Vellas B, Sano M, Aisen P, Sevigny J (2015) OC24: Randomized, double-blind, placebo controlled studies to evaluate treatment with aducanumab (BIIB037) in patients with early Alzheimer's disease: Phase 3 study design. J Prev Alzheimers Dis 2, 287.
9. Dukart J, Sambataro F, Lasser R, Nikolcheva T, Ostrowitzki S, Santarelli L, Volz D, Fontoura P, Bertolino A (2015) OC45: Reduction of amyloid-with gantenerumab for treatment of prodromal 298 Alzheimer's disease-post hoc analyses from the phase 3 SCarlet RoAD trial. J Prev Alzheimers Dis 2, 299.
10. The inflammatory Cerebral Amyloid Angiopathy and Alzheimer's disease Biomarkers International Network (iCA-), (https://sites.google.com/site/icabinternationalnet work). Accessed February 8, 2016.
11. Piazza F (2015) OC23: CSF biomarkers for amyloid related imaging abnormalities (ARIA) in immunotherapy trials of Alzheimer's disease and cerebral amyloid angiopathy: Report from the iCA International Network. J Prev Alzheimers Dis 2, 286-287.
12. Werring DJ, Sperling R (2013) Inflammatory cerebral amyloid angiopathyand amyloid-modifying therapies:Variations on the same ARIA? Ann Neurol 73, 439-441.
13. Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, Nitrini R, Sakaguchi H, Brioschi M, Billo G, Colombo A, Lanzani F, Piscosquito G, Carriero MR, Giaccone G, Tagliavini F, Ferrarese C, DiFrancesco JC (2013) Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloid-modifying therapies. Ann Neurol 73, 449-458.
14. Auriel E, Charidimou A, Gurol ME, Ni J, Van Etten ES, Martinez-Ramirez S, Boulouis G, Piazza F, DiFrancesco JC, Frosch MP, Pontes-Neto OV, Shoamanesh A, Reijmer Y, Vashkevich A, Ayres AM, Schwab KM, Viswanathan A, Greenberg SM (2016) Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathyrelated inflammation. JAMA Neurol 73, 197-202.
15. Boncoraglio GB, Piazza F, Savoiardo M, Farina L, DiFrancesco JC, Prioni S, Tagliavini F, Parati EA, GiacconeG (2015) Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-A autoantibodies. J Alzheimers Dis 45, 363-367.
16. Carmona-Iragui M, Fernández-Arcos A, Alcolea D, Piazza F, Morenas E, Antón-Aguirre S, Sala I, Clarimon Jordi, Dols-Icardo O, Camacho V, Sampedro F, Munuera Josep, Nuñez-Marin F, Lleó A, Fortea J, Gómez-Ansón B, Blesa R (2015) Cerebrospinal fluid anti-amyloid-autoantibodies and amyloid PET in cerebral amyloid angiopathy-related inflammation. J Alzheimers Dis 50, 1-7.
17. DiFrancesco JC, Touat M, Caulo M, Gallucci M, Garcin B, Levy R, Uncini A, Piazza F (2015) Recurrence of cerebral amyloid angiopathy-related inflammation: A report of two cases from the iCA international network. J Alzheimers Dis 46, 1071-1077.